Brokers Set Expectations for ABCL Q1 Earnings

AbCellera Biologics Inc. (NASDAQ:ABCL) – Leerink Partnrs issued their Q1 2026 earnings estimates for AbCellera Biologics in a note issued to investors on Wednesday, April 16th. Leerink Partnrs analyst P. Souda anticipates that the company will post earnings of ($0.16) per share for the quarter. The consensus estimate for AbCellera Biologics’ current full-year earnings is ($0.59) per share. Leerink Partnrs also issued estimates for AbCellera Biologics’ Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.17) EPS and Q4 2026 earnings at ($0.17) EPS.

Other equities research analysts have also issued research reports about the stock. Benchmark reissued a “hold” rating on shares of AbCellera Biologics in a report on Monday, March 3rd. Stifel Nicolaus decreased their price target on shares of AbCellera Biologics from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, February 28th. Finally, KeyCorp boosted their price objective on shares of AbCellera Biologics from $4.00 to $5.00 and gave the stock an “overweight” rating in a research report on Wednesday.

AbCellera Biologics Stock Up 1.3 %

NASDAQ:ABCL opened at $2.42 on Friday. The firm has a market cap of $721.13 million, a PE ratio of -3.97 and a beta of 0.50. The company’s 50-day moving average price is $2.52 and its two-hundred day moving average price is $2.77. AbCellera Biologics has a 12 month low of $1.89 and a 12 month high of $4.34.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Capital World Investors acquired a new position in AbCellera Biologics during the fourth quarter valued at approximately $23,245,000. Two Sigma Investments LP grew its stake in shares of AbCellera Biologics by 28.6% in the fourth quarter. Two Sigma Investments LP now owns 3,257,311 shares of the company’s stock valued at $9,544,000 after buying an additional 723,676 shares in the last quarter. Two Sigma Advisers LP increased its holdings in AbCellera Biologics by 19.8% during the fourth quarter. Two Sigma Advisers LP now owns 2,608,400 shares of the company’s stock worth $7,643,000 after buying an additional 430,800 shares during the last quarter. Tang Capital Management LLC increased its holdings in AbCellera Biologics by 12.3% during the fourth quarter. Tang Capital Management LLC now owns 2,582,816 shares of the company’s stock worth $7,568,000 after buying an additional 282,816 shares during the last quarter. Finally, Guardian Partners Inc. bought a new stake in AbCellera Biologics during the fourth quarter worth $5,413,000. Institutional investors and hedge funds own 61.42% of the company’s stock.

AbCellera Biologics Company Profile

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.